Archives of Dermatological Research

, Volume 297, Issue 2, pp 94–98 | Cite as

An insertion/deletion polymorphism in the gene encoding angiotensin converting enzyme is not associated with generalised vitiligo in an English population

  • Samia Akhtar
  • Nikos G. Gavalas
  • David J. Gawkrodger
  • Philip F. Watson
  • Anthony P. Weetman
  • E. Helen Kemp
Short Communication


Vitiligo is an acquired hypomelanotic skin disorder characterised by circumscribed depigmented macules resulting from the loss of functional melanocytes from the cutaneous epidermis and autoimmunity has been suggested to play a role in the pathogenesis of the disease. Recently, an insertion/deletion (I/D) polymorphism of a 287-base pair repetitive sequence in intron 16 of the angiotensin converting enzyme (ACE) gene has been associated with autoimmune disease and with the development of vitiligo. In this study, the distribution of ACE gene I/D genotypes was investigated in a population of 106 English patients with generalised (non-segmental) vitiligo and 174 ethnically matched healthy controls using a restriction fragment length polymorphism-polymerase chain reaction genotyping method. No significant difference in the frequencies of II, ID and DD genotypes was detected between vitiligo patients and control subjects (P=0.35). The same result was evident for the genotype distribution in vitiligo patients with an autoimmune disease and for those without when compared with controls (P=0.33 and P=0.53, respectively). In addition, the results indicated that the D allele was not significantly over-represented in the group of patients with vitiligo compared with controls (P=0.42) and that this was also the case for patients with and without associated autoimmunity (P=0.40 and P=0.62, respectively).


Angiotensin converting enzyme Autoimmunity Genetic susceptibility Melanocyte Gene polymorphism Vitiligo 


  1. 1.
    Alkhateeb A, Stetler GL, Old W, Talbert J, Uhlhorn C, Taylor M, Fox A, Miller C, Dills DG, Ridgway EC, Bennett DC, Fain PR, Spritz RA (2001) Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p313-p322. Hum Mol Genet 11:661–667CrossRefGoogle Scholar
  2. 2.
    Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilbrund B, Yecheskel G (1996) Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 105:84–88CrossRefPubMedGoogle Scholar
  3. 3.
    Bhatia PS, Mohan L, Pandey ON, Singh KK, Arora SK, Mukhija RD (1992) Genetic nature of vitiligo. J Dermatol Sci 4:180–184PubMedCrossRefGoogle Scholar
  4. 4.
    Blomhoff A, Kemp EH, Gawkrodger DJ, Weetman AP, Husebye ES, Akselsen A, Lie BA, Undlien DE (2005) CTLA4 polymorphisms are associated with vitiligo in patients with concomitant autoimmune diseases. Pigment Cell Res 18:55–58PubMedCrossRefGoogle Scholar
  5. 5.
    Cui J, Arita Y, Bystryn J-C (1995) Characterisation of vitiligo antigens. Pigment Cell Res 8:53–59PubMedCrossRefGoogle Scholar
  6. 6.
    Czernobilsky H, Fiehn W, Ziegler R (1985) Comparison of serum angiotensin-converting enzyme in Graves’ disease, toxic nodular goiter, and other thyroid conditions. Klin Wochenschr 63:518–522CrossRefPubMedGoogle Scholar
  7. 7.
    Fain PR, Gowan K, LaBerge GS, Alkhateeb A, Stetler GL, Talbert J, Bennett DC, Spritz RA (2003) A genomewide screen for generalised vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet 72:1560–1564PubMedCrossRefGoogle Scholar
  8. 8.
    Gilhar A, Zelickson B, Ulman Y, Etzioni A (1995) In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 105:683–686CrossRefPubMedGoogle Scholar
  9. 9.
    Hann S-K, Nordlund J (2000) Vitiligo. Blackwell Science, Oxford, UKGoogle Scholar
  10. 10.
    Hooper NM (1991) Angiotensin converting enzyme: implications from molecular biology for its physiological functions. Int J Biochem 23:641–647CrossRefPubMedGoogle Scholar
  11. 11.
    Jin SY, Park HH, Li GZ, Lee HJ, Hong MS, Hong SJ, Park HK, Chung JH, Lee MH (2004) Association of angiotensin converting enzyme gene I/D polymorphism of vitiligo in Korean population. Pigment Cell Res 17:84–86CrossRefPubMedGoogle Scholar
  12. 12.
    Kemp EH, Gawkrodger DJ, MacNeil S, Watson PF, Weetman AP (1997) Detection of tyrosinase autoantibodies in vitiligo patients using 35 S-labelled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 109:69–73PubMedCrossRefGoogle Scholar
  13. 13.
    Kemp EH, Ajjan RA, Waterman EA, Gawkrodger DJ, Cork MC, Watson PF, Weetman AP (1999) Analysis of a cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism in patients with vitiligo. Br J Dermatol 140:73–78CrossRefPubMedGoogle Scholar
  14. 14.
    Kozlowski S, Corr M, Takeshita T, Boyd LF, Pendleton CD, Germain RN, Berzofsky JA, Margulies DH (1992) Serum angiotensin converting enzyme activity processes a human immunodeficiency virus 1 g160 peptide for presentation by major histocompatibility complex class I molecules. J Exp Med 175:1417–1422CrossRefPubMedGoogle Scholar
  15. 15.
    Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee H-G, Garbe C (2001) HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 116:891–897CrossRefPubMedGoogle Scholar
  16. 16.
    Lin M-H, Tseng C-H, Tseng C-C, Huang C-H, Chong C-K, Tseng C-P (2001) Real-time PCR for rapid genotyping of angiotensin converting enzyme insertion/deletion polymorphism. Clin Biochem 34:661–666CrossRefPubMedGoogle Scholar
  17. 17.
    Majumder PP, Nordlund JJ, Nath SK (1993) Pattern of familial aggregation of vitiligo. Arch Dermatol 129:994–998CrossRefPubMedGoogle Scholar
  18. 18.
    McCormack WT, Bradley CA, Kristensen DL, She JX (2001) Genetics of vitiligo susceptibility: association studies of immune response genes. Pigment Cell Res 14:231Google Scholar
  19. 19.
    Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJ, Lalioti MD, Mullis PE, Antonarakis, SE, Kawasaki K, Asakawa S, Ito F, Shimizu N (1997) Positional cloning of the APECED gene. Nat Genet 17:393–398CrossRefPubMedGoogle Scholar
  20. 20.
    Nath SK, Majumder PP, Nordlund JJ (1994) Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 55:981–990PubMedGoogle Scholar
  21. 21.
    Norris DA, Kissinger RM, Naughton GK, Bystryn J-C (1998) Evidence for immunologic mechanisms in human vitiligo: patients’ sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 90:783–789CrossRefGoogle Scholar
  22. 22.
    Ochi Y, DeGroot LJ (1969) Vitiligo in Graves’ disease. Ann Intern Med 71:935–940PubMedGoogle Scholar
  23. 23.
    Ogg GS, Dunbar PR, Romero P, Chen J-L, Cerundolo V (1998) High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188:1203–1208CrossRefPubMedGoogle Scholar
  24. 24.
    Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS (1998) Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 111:1034–1039CrossRefPubMedGoogle Scholar
  25. 25.
    Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP (1999) Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 96:2982–2987CrossRefPubMedGoogle Scholar
  26. 26.
    Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardigo M, Borroni G, Martinetti M, Badulli C, Necker A, Giachino C (2001) Specific cytotoxic T lymphocyte responses against MelanA/MART1, tyrosinase and Gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117:326–332CrossRefPubMedGoogle Scholar
  27. 27.
    Papadopoulos K, Melander O, Orho-Melander M, Groop LC, Carlsson M, Hallengren B (2000) Angiotensin converting enzyme (ACE) gene polymorphism in sarcoidosis in relation to associated autoimmune disease. J Int Med 247:71–77CrossRefGoogle Scholar
  28. 28.
    Rigat B, Hubert C, Alhenc-Getes F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343–1346PubMedCrossRefGoogle Scholar
  29. 29.
    Rigat B, Hubert C, Corvol P, Soubrier F (1992) PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene. Nucleic Acids Res 20:1433PubMedCrossRefGoogle Scholar
  30. 30.
    Rosenberg SA, White DE (1996) Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 19:81–84PubMedGoogle Scholar
  31. 31.
    Scholzen T, Armstorng CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC (1998) Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 7:81–96CrossRefPubMedGoogle Scholar
  32. 32.
    Scholzen TE, Stander S, Riemann H, Brzoska T, Luger TA (2003) Modulation of cutaneous inflammation by angiotensin converting enyme. J Immunol 170:3866–3873PubMedGoogle Scholar
  33. 33.
    Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N (1994) The role of tyrosinase in autoimmune vitiligo. Lancet 344:1049–1052CrossRefPubMedGoogle Scholar
  34. 34.
    Spritz RA, Gowan K, Bennett DC, Fain PR (2004) Novel vitiligo susceptibility loci on chromosomes 7 (ASI2) and 8 (ASI3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet 74:188–191CrossRefPubMedGoogle Scholar
  35. 35.
    Tastan HB, Akak A, Orkunoglu FE, Arca E, Inal A (2004) Association of HLA class I antigens and HLA class II alleles with vitiligo in a Turkish population. Pigment Cell Res 17:181–184CrossRefPubMedGoogle Scholar
  36. 36.
    Vuk-Pavlovic Z, Rohrbach MS (1988) An in vitro model for the induction of angiotensin converting enzyme in sarcoidosis: possible parallels to the immune response Clin Exp Immunol 72:499–504Google Scholar
  37. 37.
    Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19:251–253PubMedCrossRefGoogle Scholar
  38. 38.
    Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD (2000) Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 192:1637–1644CrossRefPubMedGoogle Scholar
  39. 39.
    Zamani M, Spaepen M, Sghar SS, Huang C, Westerhof W, Nieuweboer-Krobotova L, Cassiman JJ (2001) Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol 145:90–94CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Samia Akhtar
    • 1
  • Nikos G. Gavalas
    • 1
  • David J. Gawkrodger
    • 2
  • Philip F. Watson
    • 1
  • Anthony P. Weetman
    • 1
  • E. Helen Kemp
    • 1
  1. 1.Division of Clinical Sciences (North)University of Sheffield, Northern General HospitalSheffieldUK
  2. 2.Department of DermatologyRoyal Hallamshire HospitalSheffieldUK

Personalised recommendations